Visioneering Technologies, Inc. announced the appointment of Dr. Allan E. Rubenstein as an independent non-executive director, and the pending retirement of Zita Peach from its Board of Directors. Dr. Rubenstein will commence his term on 29 June 2022. He is a highly experienced public company board director, a successful entrepreneur, and a respected medical doctor.

He served for 29 years on the board of The Cooper Companies, Inc., including as either Chairman or Lead Independent Director for all but two of those years. The Cooper Companies, Inc. is the parent company of CooperVision, one of the largest contact lens companies in the world. Dr. Rubenstein is a neurologist known for his pioneering work on research and treatment of neurofibromatosis ("NF"), a rare genetic disorder, and has become an expert due to his commercial interests in genomics, ocular conditions and treatments, medical devices, and women's health.

He started the first multidisciplinary clinic devoted to NF in the world at Mount Sinai School of Medicine, which over the years became the model for more than 100 other NF clinics in the U.S., Europe, and South America. Dr. Rubenstein achieved success early in his career by founding, growing, and selling a mobile CT and MRI scanning company in New York City. After growing the company both organically and through acquisition to serve multiple states, he sold the business.

He then founded and served as CEO of NexGenix Pharmaceuticals, which developed drugs for cancer and genetic disorders. He also joined the board of Bioclinica, which provides imaging modalities for clinical trials (Bioclinica merged in 2021 to become Clario, a private company). Most recently, he joined the boards of two private companies that are commercializing advances in treatments for conditions caused by protein misfolding (Plex Pharmaceuticals) and in wavelength filtering polymers for contact lenses (Coloursmith Labs).

He also joined the Tufts University Graduate School of Biomedical Sciences advisory board, a program that engages stakeholders from science, private equity and governmental sectors to commercialize advances in medicine. Dr. Rubenstein earned his Bachelor of Arts degree from Cornell University and his medical degree from the Tufts University School of Medicine. Ms. Zita Peach will retire on 18 August 2022, subsequent to the next scheduled quarterly meeting of the Board of Directors.

She has served as an independent non executive director of VTI since February 2017, including as Chair of the Nomination and Remuneration Committee and as a member of the Audit and Risk Committee.